Media stories about Akebia Therapeutics (NASDAQ:AKBA) have trended somewhat positive this week, according to Accern. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Akebia Therapeutics earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.6766821776914 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
A number of equities research analysts have recently commented on AKBA shares. Royal Bank of Canada started coverage on shares of Akebia Therapeutics in a report on Thursday, September 14th. They set a “sector perform” rating and a $17.00 price target on the stock. Mizuho started coverage on shares of Akebia Therapeutics in a report on Wednesday, October 4th. They set a “buy” rating and a $24.00 price target on the stock. Zacks Investment Research cut shares of Akebia Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. HC Wainwright reiterated a “buy” rating and set a $24.00 price target on shares of Akebia Therapeutics in a report on Wednesday, November 15th. Finally, ValuEngine cut shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company’s stock. Akebia Therapeutics currently has an average rating of “Buy” and a consensus price target of $22.20.
Shares of Akebia Therapeutics (NASDAQ:AKBA) opened at $15.58 on Friday. Akebia Therapeutics has a fifty-two week low of $8.58 and a fifty-two week high of $20.25. The stock has a market cap of $736.45, a P/E ratio of -4.93 and a beta of 0.87.
ILLEGAL ACTIVITY WARNING: This article was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.com-unik.info/2018/01/12/akebia-therapeutics-akba-receiving-somewhat-favorable-news-coverage-accern-reports.html.
About Akebia Therapeutics
Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).
What are top analysts saying about Akebia Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Akebia Therapeutics and related companies.